
PEARL Trial: A Blow to Rapamycin’s Healthspan Narrative?
Physionic
Oct 14, 2024
Mindsip insights from this episode:
Confirm safety of low-dose rapamycin in PEARL trial
The PEARL trial was primarily a safety study and concluded that there were no serious adverse effects linked to rapamycin at the tested doses over 48 weeks.
Demand funding for definitive rapamycin clinical trials
A leading expert on rapamycin expressed immense frustration that funders have not stepped up to finance the definitive clinical trials needed to properly evaluate the drug.
Acknowledge limitations of healthy participants in study results
The study's ability to show significant effects was limited because many of the enrolled participants were already quite healthy.
Achieve small gains in bone and muscle with rapamycin
Even with a much lower than intended dose, the 10mg rapamycin group showed small improvements in bone mineral content and muscle mass.
Address dosing flaws in rapamycin trial for accurate results
The recent PEARL trial on rapamycin accidentally used doses that were only about 30% of the intended amount due to a packaging and bioavailability issue.
More from
Physionic
You also might be interested in
Psychedelics, Depression, and the Brain: A Breakthrough Framework for Mental Health
Can Injectable MDMA Become the Next Biohack in 2026? RFK Jr. vs FDA – Rick Doblin
Doctors Won't Tell You This! - Dark Truth About Antidepressants & How Big Pharma Fooled Everyone
Arthritis BREAKTHROUGH From a Common $6 Drug
AMA #70: Nicotine: impact on cognitive function, performance, and mood, health risks, delivery modalities, and smoking cessation strategies